GlassScriptPhysician profile
Krystal R Foree
NPI 1790935245
$2,619.84
in general payments reported to CMS, 2019-2025
28 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $264 · 2021: $44.48 · 2022: $494 · 2023: $759 · 2024: $418 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.00 | 2019-2025 | |
| Pfizer INC. | $222.54 | 2019-2025 | |
| Coopersurgical, INC. | $203.22 | 2019-2024 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $179.24 | 2022-2023 | |
| Astellas Pharma US INC | $165.27 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $164.70 | 2019-2025 | |
| Biogen, INC. | $147.37 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $145.13 | 2019-2024 | Wegovy |
| Shield Therapeutics INC | $120.95 | 2023-2025 | Accrufer |
| Organon LLC | $80.67 | 2023-2024 | Jada System |
| Agile Therapeutics, INC. | $62.97 | 2022-2024 | Twirla |
| Avion Pharmaceuticals | $60.73 | 2019-2022 | |
| Therapeuticsmd, INC. | $49.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $35.66 | 2019-2024 | Gardasil, Gardasil 9 |
| Millicent US INC | $33.34 | 2025 | Femlyv, Intrarosa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $31.27 | 2024-2025 | Myfembree |
| Mission Pharmacal Company | $25.74 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $21.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.53 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.51 | 2019 | |
| Dexcom, INC. | $18.28 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $17.55 | 2024 | Zepbound |
| Currax Pharmaceuticals LLC | $17.39 | 2023 | Contrave, Onzetra Xsail |
| Mallinckrodt Enterprises LLC | $15.32 | 2019 | |
| Allergan, INC. | $14.91 | 2019 | |
| Exeltis, USA INC. | $14.51 | 2022 | |
| Olympus America INC. | $12.89 | 2023 | Olympus |
| Lupin INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Foree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.